E3S Web Conf.
Volume 233, 20212020 2nd International Academic Exchange Conference on Science and Technology Innovation (IAECST 2020)
|Number of page(s)||4|
|Section||BFS2020-Biotechnology and Food Science|
|Published online||27 January 2021|
A preliminary study on the synthetic lethal effect of berberine and olaparib on pancreatic cancer cells and its mechanism
1 Clinical Department of Guangdong Metabolic Disease Research Centre of Integrated Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, No.19 Nonglinxia Road, 510000, Guangzhou, China.
2 Precision Medical Engineering Research Center for Esophageal Cancer of Guangdong Province at The First Affiliated Hospital of Guangdong Pharmaceutical University, No.19 Nonglinxia Road, 510000, Guangzhou, China.
# Contribute equally to this work.
* Correspondence Author: email@example.com
Pancreatic cancer is a kind of malignant tumor with high mortality rate. Early operation and late chemoradiotherapy are the treatment criteria, but the prognosis is still poor. Berberine, an alkaloid compound present in many herbal plants, is capable of inducing oxidative DNA damage and downregulating homologous recombination repair (HRR) in cancer cells. Poly (ADP ribose) polymerase-1 (PARP-1) is a sensor of DNA damage with key roles in DNA repair. In this study, we demonstrated that berberine and PARP inhibitor olaparib have a synthetic lethal effect on pancreatic cancer cells. The expression level of RAD51 were reduced by berberine. Correspondingly, PARP became hyperactivated in response to berberine treatment. When berberine is combined with olaparib, the expression of Rad51 and Parp are inhibited. The combination of berberine and olaparib synergistically inhibit cell activity and induce cell apoptosis. In addition, the synergistic effect of berberine and olaparib can be reversed by apoptosis inhibitor and necrosis inhibitor. Together, the results indicate that berberine combined with olaparib have a synthetic lethal effect on pancreatic cancer cells.
© The Authors, published by EDP Sciences 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.